BioNTech (BNTX) Q3 2024 earnings summary

Executive summary

• Achieved significant progress in Q3 2024, including the successful global launch of updated COVID-19 vaccines targeting new variants and advancing the oncology pipeline with new Phase 2 trials and positive data for BNT327 and mRNA cancer vaccine candidates.

• Provided strategic updates on scaling AI capabilities, hosted inaugural AI Day, and announced new partnerships.

• Maintained robust liquidity with €17.8 billion in cash and security investments at quarter-end.

Financial highlights

• Q3 2024 revenues reached €1,244.8 million, up from €895.3 million in Q3 2023, driven by early COVID-19 vaccine approvals; net profit was €198.1 million, up from €160.6 million.

• Nine-month revenues declined to €1,561.1 million from €2,340.0 million; nine-month net loss of €924.8 million versus prior year profit of €472.4 million.

• Diluted EPS for Q3 2024 was €0.81, up from €0.66; nine-month loss per share was €3.83 compared to prior year EPS of €1.94.

• Cost of sales, R&D, and SG&A expenses increased year-over-year in Q3; other operating result was negative €354.6 million, mainly due to provisions for contractual disputes.

• Cash and cash equivalents plus security investments totaled €17.8 billion as of September 30, 2024.

Outlook and guidance

• Full-year 2024 revenues expected at the low end of the €2.5–3.1 billion guidance range due to lower demand and pricing in some markets.

• Company expects to report a loss for 2024 as investments in pipeline and technology continue.

• SG&A and capex guidance each reduced by €100 million; SG&A now €600–700 million, capex €300–400 million.

• R&D expense guidance maintained at €2.4–2.6 billion; guidance excludes potential M&A or legal settlements.

• Revenue guidance sensitive to vaccination rates, price levels, and inventory write-downs.